查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678512

全球 GLP-1促效剂减重药市场：市场规模、市场份额、趋势分析（按药物、给药途径、分销管道和地区）、按细分市场预测（2025-2030 年）

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10个工作天内

价格

GLP-1促效剂减重药物市场的成长与趋势：

根据Grand View Research的最新报告，全球GLP-1促效剂减重药物市场规模预计到2030年将达到488.4亿美元，2025年至2030年期间的复合年增长率为18.54%。

减重治疗中对 GLP-1促效剂（例如 Semaglutide (Wegovy)、利拉鲁肽 (Saxenda) 和 Tirzepatide (促效剂)）的需求正在为医疗保健领域带来巨大的商机。这些药物在控制肥胖和代谢状况方面表现出了有效的效果，正在推动市场的成长。虽然Semaglutide(Wegovy) 和利拉鲁Liraglutide(Saxenda) 已经成为可靠的减重疗法，但替泽帕肽 (Zepbound) 与同类药物相比表现出了更高的疗效，并成为一种有前途的选择。这些药物透过调节食慾和提高胰岛素敏感性发挥作用，随着越来越多的临床证据支持其使用，GLP-1促效剂在肥胖症治疗中越来越受欢迎。

口服製剂的引入不仅使这些治疗方法更容易获得，而且还将扩大青睐非注射治疗方法的患者群。药局在 GLP-1促效剂的分销中发挥越来越重要的作用。零售药局因可配发 Wegovy 和 Saxenda处方笺广受欢迎，它们不仅可以提供药品，还可以为肥胖管理者提供病患教育和持续支援。凭藉便捷的药物补充和咨询服务，零售药局在支持长期减重管理方面发挥着至关重要的作用。

虽然医院药局仍然发挥着重要作用，特别是当患者开始治疗并需要密切监测时，但随着患者转向长期护理，零售药局正在发挥更重要的作用。由于医疗管理的重要性，医院药局在治疗的早期阶段非常重要，但随着病患病情稳定和治疗进展，通常会转向零售或专业药局。这些药房在提供持续治疗和提供专业服务方面发挥着至关重要的作用。

专科药局和网路药局也开始参与 GLP-1促效剂减重药的分销。这些药局可以为患者提供客製化服务，例如送货上门和个人化用药咨询，这对那些接受长期治疗方法的患者尤其有益。扩大药局的作用可以为需要持续接受减重治疗的患者提供更多的便利和支持。

肥胖症是一个重大的公共卫生问题，人们对防治肥胖症的兴趣日益浓厚，这推动了 GLP-1促效剂减重药物产业的扩张。随着人们对肥胖相关的长期健康风险（如第二型糖尿病、心血管疾病和睡眠呼吸中止症）的认识越来越广泛，对有效治疗方法的需求也日益增长。 tirzepatide同时针对GLP-1和GIP受体，其新颖的作用机制因优异的疗效而受到广泛关注，这可能进一步推动对GLP-1促效剂的需求。

随着对这些药物的需求增加，挑战也随之而来，特别是在药品分销和供应链管理领域。注射疗法的持续可用性需要强大的低温运输物流和高度重视病患教育，以优化药物使用。此外，口服製剂的开发代表着提高可及性和依从性的重要机会，为製药公司提供了服务更广泛患者群体的新途径。

GLP-1促效剂减重药市场：分析概述

  • 依药物划分，Semaglutide（wegovy）板块将在2024年以60.70%的最大销售份额领先市场，巩固其作为肥胖管理首选治疗选择的地位。Semaglutide是此类治疗领域的市场领导者，具有显着减轻体重、改善代谢健康的功效，且临床认可度不断提高。
  • 根据给药途径，肠外药物将在 2024 年以 92.7% 的销售份额引领市场。这些注射疗法每週或每两週进行一次，因其在促进长期减肥和解决胰岛素抗性等潜在代谢疾病方面被证明有效而受到青睐。
  • 按分销管道划分，零售药局部门在 2024 年占据市场主导地位，销售份额最大，为 55.46%。零售药局提供的便利性和日益增强的可及性使其成为患者使用减重药的主要网路基地台。
  • 由于医疗基础设施发达、对神经系统疾病的高度认识以及先进治疗方案的可用性等因素，预计北美将在 2024 年占据最大的市场占有率。该地区对研究和创新的高度重视进一步推动了市场成长。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. GLP-1促效剂减重药市场：驱动因素、趋势与范围

  • 母市场展望
  • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • GLP-1促效剂减重药市场：分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章 GLP-1促效剂减重药物市场：药物特定估计与趋势分析

  • GLP-1促效剂减重药市场：细分仪表板，依药物分类
  • GLP-1促效剂减重药市场：药物趋势分析（2024 年和 2030 年）
  • Semaglutide（Wegovy）
  • 利拉鲁Liraglutide（Saxenda）
  • Tirzepatide（Zepbound）
  • 其他药物

第 5 章 GLP-1促效剂减重药市场：按给药途径进行的估计和趋势分析

  • GLP-1促效剂减重药市场：细分仪表板（依给药途径划分）
  • GLP-1促效剂减重药市场：按给药途径分類的趋势分析（2024 年和 2030 年）
  • 肠外
  • 口服

6. GLP-1促效剂减重药市场：通路评估及趋势分析

  • GLP-1促效剂减重药市场：细分仪表板、通路
  • GLP-1促效剂减重药市场：通路变化分析（2024 年和 2030 年）
  • 医院药房
  • 零售药局
  • 其他药局

第 7 章 GLP-1促效剂减重药物市场：按地区分類的估计和趋势分析

  • GLP-1促效剂减重药市场占有率（按地区划分） (2024 年和 2030 年)
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 南非

第八章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司市场占有率分析（2024 年）
  • 企业热图分析（2024年）
  • 公司简介
    • Eli Lilly and Company.
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Viking Therapeutics
    • Structure Therapeutics
Product Code: GVR-4-68040-512-4

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends:

The global GLP-1 agonists weight loss drugs market size is anticipated to reach USD 48.84 billion by 2030 and is projected to grow at a CAGR of 18.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared to other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.

The introduction of oral versions would not only make these therapies more accessible but also broaden the patient base who prefer non-injection-based therapies. Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access to the medications but also patient education and ongoing support for those managing obesity. Retail pharmacies' ability to offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss.

While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition to long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift to retail or specialty pharmacies. These pharmacies play a vital role in providing continued access to therapy and offering specialized services.

Specialty pharmacies and online pharmacies are also becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access to weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education to optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity to improve accessibility and adherence, providing a new avenue for pharmaceutical companies to cater to a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights:

  • Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.
  • Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable therapies, administered either weekly or bi-weekly, are preferred due to their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.
  • Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.
  • North America accounted for the largest market share in 2024, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Agonists Weight Loss Drugs Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of obesity
      • 3.3.1.2. Increasing adoption of weight loss drug therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. High cost of treatment
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
  • 3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. GLP-1 Agonists Weight Loss Drugs Market: By Drug Estimates & Trend Analysis

  • 4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
  • 4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Semaglutide (Wegovy)
    • 4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Liraglutide (Saxenda)
    • 4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tirzepatide (Zepbound)
    • 4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Drugs
    • 4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Estimates & Trend Analysis

  • 5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
  • 5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parenteral
    • 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard
  • 6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other Pharmacies
    • 6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. GLP-1 Agonists Weight Loss Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Eli Lilly and Company.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Viking Therapeutics
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Structure Therapeutics
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 4 Global GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 8 North America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 11 U.S. GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 14 Canada GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 17 Mexico GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 21 Europe GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 24 Germany GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Germany GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 27 UK GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 UK GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 30 France GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 33 Italy GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 36 Spain GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 39 Denmark GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 42 Sweden GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 45 Norway GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 52 China GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 China GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 55 Japan GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Japan GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 58 India GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 61 South Korea GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 64 Australia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 67 Thailand GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 71 Latin America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 74 Brazil GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 77 Argentina GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 84 South Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 90 UAE GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 UAE GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 93 Kuwait GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 GLP-1 Agonists Weight Loss Drugs, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five forces Analysis
  • Fig. 14 Global GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis
  • Fig. 15 Global GLP-1 Agonists Weight Loss Drugs Market, for Semaglutide (Wegovy), 2018 - 2030 (USD Million)
  • Fig. 16 Global GLP-1 Agonists Weight Loss Drugs Market, for Liraglutide (Saxenda), 2018 - 2030 (USD Million)
  • Fig. 17 Global GLP-1 Agonists Weight Loss Drugs Market, for Tirzepatide (Zepbound), 2018 - 2030 (USD Million)
  • Fig. 18 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Drugs, 2018 - 2030 (USD Million)
  • Fig. 19 Global GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analys
  • Fig. 20 Global GLP-1 Agonists Weight Loss Drugs Market, for Parenteral 2018 - 2030 (USD Million)
  • Fig. 21 Global GLP-1 Agonists Weight Loss Drugs Market, for Oral, 2018 - 2030 (USD Million)
  • Fig. 22 Global GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis
  • Fig. 23 Global GLP-1 Agonists Weight Loss Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 24 Global GLP-1 Agonists Weight Loss Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 25 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways GLP-1 Agonists Weight Loss Drugs Market, Region 2018 -
  • Fig. 27 Regional Outlook, 2022 & 2030 GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 Global GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 29 North America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 US GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 France GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 China GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 India GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Company/Competition Categorization
  • Fig. 58 Company Market Share Analysis, 2024
  • Fig. 59 Company Market Position Analysis, 2024
  • Fig. 60 Strategy Mapping